



INVITATION

Rewriting the future of patients with schizophrenia with long-acting therapies

IMS03 - Mini Industry Session 2024
Saturday 21 September 2024
10:10-10:55 CEST
Allianz MiCo, Milan, Italy
Brown Hall 3

Scientific Committee:
David Taylor (UK) and
Domenico De Berardis (Italy)
Chair:
David Taylor (UK)

10:10	Welcome and introduction	David Taylor (UK)
10:20	Setting strong foundations: Initiation of long-acting therapies early in the disease course	María Paz Garcia-Portilla (Spain)
10:30	Unlocking the potential of long-acting therapies: The added value of longer administration intervals	Domenico De Berardis (Italy)
10:40	Discussion	All faculty, moderated by David Taylor (UK)
10:50	Closing remarks	David Taylor (UK)

Industry session financially supported by Janssen Pharmaceutica NV, a Johnson & Johnson Company, during the 37th ECNP Congress



The European Accreditation Committee in CNS (EACIC) has granted 1 CME credit to this Industry Mini Session. Both in-person and online participants can claim CME credits via the online congress platform: www.ecnp.eu/Congress2024/ECNPcongress